可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Fujino T,Hasebe N,Kikuchi K.Evidencebased usefulness of Ca antagonists and ACEIs and ARBs for the primary and secondary prevention of major cardiovascular and renal events in patients with hypertension[J]. Clin Calcium, 2005 ,15(10):1695-1708.
[2] Borghi C, Cosentino E, De Sanctis D.Angiotensinconverting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success[J]. Ital Heart J Suppl, 2005 ,6(12):769-779.
[3] 赵光胜.肾神经轴平衡失调与高血压[J].中国慢性病预防与控制,2005,13(2):49-50.
[4] Verdecchia P,Reboldi GP.Hypertension and microalbuminuria:the new detrimental duo[J].Blood Press,2004,13(4):198-211.
[5] Tylicki L,Manitius J,LysiakSzydlowska W,et al.Tubular injury: the first symptom of hypertensive kidney involvement[J]. Med Sci Monit,2003,9(4):CR135- CR141.
[6] 王海燕.肾脏病学[M].第2版.北京:人民卫生出版社,2001:1150-1151.
[7] Schmieder RE. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?[J]. J Hypertens Suppl, 2006 ,24(2):S31-S35.
[8] 吴峻,孙明,周宏研.高血压微量蛋白尿形成与血管及肾小球损害的关系[J]. 湖南医科大学学报,2002,27(6):512-514.
[9] Radermacher J,Forstermann U,Frolich J.Endotheliumderived relaxing factor influences renal vascular resistance[J].Am J Physiol,1990,259(1Pt2):F9-FI7.
[10] 陈健,房志仲.黄芪注射液的药理作用及临床应用[J].天津医科大学学报,2005,11(1):153-157.
[11]万影. 黄芪对超氧阴离子自由基的清除作用[J]. 数理医药学杂志,1998,11(1)∶61.
[12]汤日春,莫耘松,陈薇,等.黄芪对高血压病早期肾损害的保护作用[J].现代中西医结合杂志,2006,15(1):26-27.
[13]高琳琳,李福荣.依那普利对自发性高血压大鼠血压、一氧化氮及诱导型一氧化氮合酶的影响[J]. 广西医科大学学报,2003,20(6):884-885.